Minerva Biotechnologies Licenses Sendai Virus Technology for Stem Cell Generation

Minerva Biotechnologies and ID Pharma Co., Ltd. (formerly DNAVEC) announced today that they have signed an agreement granting Minerva worldwide rights to use and commercialize their non-integrating Sendai virus vectors, together with Minerva’s proprietary …

[Read the full article here]

Comments are closed.